All News

Today is September 19, 2021. All times in Eastern Daylight Time.

Fusionex Signs MoU with Alliance Islamic Bank to Accelerate SMEs’ Halal Business Growth

09/19/2021 - 07:00 PM

BUSINESS WIRE
Rio Tinto to triple Weipa solar capacity and add battery storage to help power operations

09/19/2021 - 06:59 PM

BUSINESS WIRE
Office of Traffic Safety, Safety Center Hosts “Superheroes” Day Full of Biking, Walking Safety Activities

09/19/2021 - 02:00 PM

BUSINESS WIRE
AD Ports Group and Aqaba Development Corporation Sign Agreement for Tourism and Maritime Enhancement Projects in Aqaba - Jordan

09/19/2021 - 12:26 PM

BUSINESS WIRE
DeSHAZO Acquires Proto Machine Works

09/19/2021 - 11:34 AM

BUSINESS WIRE
Datopotamab Deruxtecan Shows Encouraging Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer with Actionable Genomic Alterations

09/19/2021 - 11:30 AM

BUSINESS WIRE
Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021

09/19/2021 - 11:30 AM

BUSINESS WIRE
Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021

09/19/2021 - 11:30 AM

BUSINESS WIRE
Tratamento com anticorpo monoclonal da Celltrion para COVID-19, regdanvimabe (CT-P59) é o primeiro tratamento para COVID-19 autorizado e aprovado pelo Ministério Coreano de Segurança de Alimentos e Medicamentos (MFDS)

09/19/2021 - 10:04 AM

BUSINESS WIRE
Barrett-Jackson Inaugural Houston Auction Hits $37.5 Million Fueled by $1.98 Million Sale of Porsche 928 Driven by Tom Cruise in “Risky Business”

09/19/2021 - 09:50 AM

BUSINESS WIRE
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)

09/19/2021 - 07:30 AM

BUSINESS WIRE
Personalis Receives New VA MVP Task Order and Record Quarterly Orders From Oncology Customers; Reconfirms Total Revenue Outlook for 2021 with Further Accelerated Oncology Growth

09/18/2021 - 10:50 PM

BUSINESS WIRE
“We’ve run out of staff. Kenney’s fourth wave is collapsing the system.” Rory Gill, President CUPE Alberta

09/18/2021 - 10:12 PM

BUSINESS WIRE
Epsilyte Moving Expandable Polystyrene (EPS) Prices up to Keep Pace With Rising Feedstock Costs

09/18/2021 - 09:13 PM

BUSINESS WIRE
Společnost Zynga představuje ReVamp, první společenskou hru pro více hráčů pro Snapchat

09/18/2021 - 02:27 PM

BUSINESS WIRE
未来に適応した経営モデルを当フォーラムに求めるべき理由

09/18/2021 - 11:56 AM

BUSINESS WIRE
IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer

09/18/2021 - 11:30 AM

BUSINESS WIRE
IMFINZI Plus Chemotherapy Tripled Patient Survival at Three Years in the CASPIAN Phase III Trial in Extensive-Stage Small Cell Lung Cancer

09/18/2021 - 11:30 AM

BUSINESS WIRE
N2 Packaging Systems, LLC élargit son portefeuille international de brevets pour le conditionnement du cannabis.

09/18/2021 - 10:34 AM

BUSINESS WIRE
Unifrax organiza la ceremonia de inauguración para la línea de producción de SiFAB™

09/18/2021 - 10:23 AM

BUSINESS WIRE
Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)

09/18/2021 - 09:34 AM

BUSINESS WIRE
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting

09/18/2021 - 09:05 AM

BUSINESS WIRE
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer

09/18/2021 - 09:05 AM

BUSINESS WIRE
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer

09/18/2021 - 09:05 AM

BUSINESS WIRE
ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer

09/18/2021 - 09:05 AM

BUSINESS WIRE

1 2 3 4 5 6 7 8 9 10 11 ... 629

Next »

Search